WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- A new spinal cord implant may help people with spinal muscular atrophy (SMA) ...
A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.
In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.
The first-in-human SCS trial saw all three SMA patients able to increase their walking distance within six minutes to 20 meters.
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
in treating individuals with spinal muscular atrophy (SMA) Type 2. The randomised, sham-controlled study assessed the efficacy and safety of the gene therapy in treatment-naïve individuals aged ...
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Health activists demand government action to reduce the cost of SMA medicines, citing constitutional obligations and ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...